Virus-Like Particle-Mediated Vaccination against Interleukin-13 May Harbour General Anti-Allergic Potential beyond Atopic Dermatitis

Virus-like particle (VLP)-based anti-infective prophylactic vaccination has been established in clinical use. Although validated in proof-of-concept clinical trials in humans, no VLP-based therapeutic vaccination against self-proteins to modulate chronic disease has yet been licensed. The present re...

Descripción completa

Detalles Bibliográficos
Autores principales: Foerster, John, Molęda, Aleksandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7232523/
https://www.ncbi.nlm.nih.gov/pubmed/32294982
http://dx.doi.org/10.3390/v12040438

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7232523/
https://www.ncbi.nlm.nih.gov/pubmed/32294982
http://dx.doi.org/10.3390/v12040438

Ejemplares similares